SELLAS Stock Jumps After Company Reports Phase 3 Trial Met Goal
The pick
SELLAS Life Sciences (SLS) had the biggest jump in trading volume compared with its usual level, at 16.9x its 30-day average. The stock rose 156.36%.
What happened
SELLAS announced topline results from its Phase 3 REGAL trial of galinpepimut-S (GPS), a cancer vaccine for acute myeloid leukemia (AML). The company said the trial met its primary endpoint of overall survival.
The company reported a 41% reduction in the risk of death for GPS, with a hazard ratio of 0.59 and a two-sided p-value of 0.035. Median overall survival was 24.0 months for patients on GPS and 14.7 months for those on best available treatment. The trial randomized 126 patients 1:1 between the two groups.
SELLAS said GPS was generally well tolerated, with no new safety signals identified. It said most treatment-related side effects were mild to moderate, most commonly reactions at the injection site.
The company said it plans to meet with the U.S. Food and Drug Administration (FDA) to discuss an accelerated filing strategy. It also said it plans to advance preparations for a Biologics License Application (BLA) submission for GPS in the first half of 2027. Later on November 17, SELLAS announced an underwritten public offering of $150.0 million of its common stock. It intends to give the underwriters a 30-day option to buy up to an additional $22.5 million of shares.
Sources: [company announcement, SEC filing] [press release]
What news reports said
Investing.com, in an article carried by Yahoo Finance, reported that SELLAS shares dropped 10% in after-hours trading on Tuesday after the company announced the $150 million offering [Yahoo Finance].
The numbers
Previous close: $7.47
Close: $19.15
Change: +156.36%
Volume: 118,286,791
30-day average volume: 6,990,574
Volume multiple: 16.9x
Behind the move: an earnings report
SLS's most unusual trading day in 21 months
Its sector (Health Care, XLV) moved -1.41% that day
Pro: SLS has had 8+ earlier days at 5x+ normal volume since 2017. Pro members see what it did over the next 5 and 20 trading days after each one. See Pro
Curious what usually happens after a stock trades 17x its normal volume? Pro members can ask questions like that in plain English and get results across every U.S. stock since 2016. See what Pro includes
More coverage
Sellas Life Sciences shares surge 175% after cancer vaccine succeeds in late-stage trial (Yahoo Finance)
Pro: 9 more stocks made Tuesday's unusual-volume top 10, the next one at 9.0x its normal level. Pro members can also test any setup in plain English on every U.S. stock since 2016 ("what happened after stocks traded 17x their normal volume?"), and get the full top 10 every morning plus intraday alerts on big moves. 25 of 25 founding spots left: $9/month, locked in for as long as you stay ($14 after Dec 31 or when the spots are gone). Claim a founding spot